Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Nicole M. Cruz"'
Autor:
Gail J. Roboz, Ellen K. Ritchie, Yulia Dault, Linda Lam, Danielle C. Marshall, Nicole M. Cruz, Hsiao-Ting C. Hsu, Duane C. Hassane, Paul J. Christos, Cindy Ippoliti, Joseph M. Scandura, Monica L. Guzman
Publikováno v:
Haematologica, Vol 103, Iss 8 (2018)
Acute myeloid leukemia carries a dismal prognosis in older patients. The objective of this study was to investigate the safety and efficacy of decitabine combined with the CXCR4 antagonist plerixafor in newly diagnosed older patients with acute myelo
Externí odkaz:
https://doaj.org/article/373fb383089440989a2d3b9efeec3de1
Autor:
Ernesto Salcedo, Nicole M. Cruz, Xuan Ly, Beth A. Welander, Kyle Hanson, Eugene Kronberg, Diego Restrepo
Publikováno v:
Open Biology, Vol 3, Iss 5 (2013)
Major histocompatibility class I (MHCI) molecules are well known for their immunological role in mediating tissue graft rejection. Recently, these molecules were discovered to be expressed in distinct neuronal subclasses, dispelling the long-held ten
Externí odkaz:
https://doaj.org/article/009cd2aa80f74b76b582ed887c661323
Publikováno v:
Expert review of hematology. 13(1)
Introduction: Recent advances in the prognostic scheme and treatment of primary and secondary myelofibrosis (MF) have resulted in an overwhelming amount of clinical information to assimilate. The authors believe a comprehensive review that summarizes
Autor:
Danielle C. Marshall, Cindy Ippoliti, Monica L. Guzman, Hsiao-Ting C. Hsu, Nicole M. Cruz, Linda Lam, Duane C. Hassane, Ellen K. Ritchie, Yulia Dault, Gail J. Roboz, Joseph M. Scandura, Paul J. Christos
Publikováno v:
Haematologica
Acute myeloid leukemia carries a dismal prognosis in older patients. The objective of this study was to investigate the safety and efficacy of decitabine combined with the CXCR4 antagonist plerixafor in newly diagnosed older patients with acute myelo
Autor:
Katarzyna Dulik, Agnieszka Wierzbowska, Damian Mikulski, Janusz Hałka, Krzysztof Wozniczka, Agnieszka Pluta, Tomasz Wróbel, Malgorzata Razny, Nuria Mencia-Trinchant, Andrzej Szczepaniak, Nicole M. Cruz, Agata Obara, Gail J. Roboz, Pinkal Desai, Sebastian Giebel, Michal Soin, Magdalena Dutka, Marta Sobas, Ellen K. Ritchie, Michael B. Samuel, Ewelina Perdas, Marek Hus, Justin D. Kaner, Maria Bieniaszewska, Lidia Gil, Wojciech Fendler, Piotr Stelmach, Edyta Cichocka, Anna Czyż, Marta Antonina Libura, Magdalena Czemerska, Elżbieta Patkowska, Monica L. Guzman, Jolanta Wozniak, Sangmin Lee, Agnieszka Kopacz, Tomasz Gromek, Jerzy Holowiecki, Anna Kopińska, Karol Wojcik, Grzegorz Helbig
Publikováno v:
Blood. 138:3453-3453
Background: Measurable residual disease (MRD) is an important biomarker in acute myeloid leukemia (AML). Among patients who achieve remission after standard chemotherapy, detection of MRD (MRD+) after two cycles of intensive chemotherapy, at the end
Autor:
Agata Obara, Nuria Mencia-Trinchant, Marta Sobas, Michael B. Samuel, Grzegorz Helbig, Andrzej Szczepaniak, Piotr Stelmach, Anna Czyż, Ellen K. Ritchie, Jolanta Wozniak, Jerzy Holowiecki, Agnieszka Wierzbowska, Anna Kopińska, Nicole M. Cruz, Tomasz Wróbel, Magdalena Czemerska, Pinkal Desai, Tomasz Gromek, Sebastian Giebel, Elżbieta Patkowska, Alicja Sadowska-Klasa, Janusz Hałka, Michal Soin, Beata Blajer-Olszewska, Malgorzata Razny, Karol Wojcik, Justin D. Kaner, Jan Maciej Zaucha, Katarzyna Dulik, Lidia Gil, Edyta Cichocka, Krzysztof Wozniczka, Agnieszka Pluta, Marek Hus, Gail J. Roboz, Monica L. Guzman, Marta Antonina Libura, Sangmin Lee, Tadeusz Robak
Publikováno v:
Blood. 136:3-4
Background: AML is the most common acute leukemia in adults. While most adults < 60 years achieve complete remission (CR) with intensive induction chemotherapy, approximately one third have primary refractory disease and, overall, the majority of AML
Autor:
Roman Galetto, Nicole M. Cruz, Julianne Smith, Monica L. Guzman, Nathan Ewing-Crystal, Duane C. Hassane, Linda Lam, Gail J. Roboz, Agnès Gouble, Mayumi Sugita
Publikováno v:
Leukemia & Lymphoma. 59:978-982
Acute myelogenous leukemia (AML) is a deadly disease characterized by high relapse rates even in patients who initially achieve complete remission. Standard therapy for AML has remained largely unc...
Publikováno v:
International Journal of Laboratory Hematology. 39:53-60
Treatment of acute myelogenous leukemia (AML) over the past four decades remains mostly unchanged and the prognosis for the majority of patients remains poor. Most of the significant advances that have been observed are in defining cytogenetic abnorm
Publikováno v:
American Journal of Gastroenterology. 111:S822-S823
Autor:
Nicole M. Cruz, Linda Lam, Gail J. Roboz, Julianne Smith, Agnès Gouble, Monica L. Guzman, Mayumi Sugita, Roman Galetto
Publikováno v:
Blood. 128:1693-1693
Background: CD123, the trans-membrane alpha chain of the interleukin-3 receptor (IL-3RA) is overexpressed in acute myeloid leukemia (AML) and distinguishes leukemia stem cells from their normal counterparts. There are several novel therapeutics under